Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CSL Behring
With
Blood and Marrow Transplant Clinical Trials Network
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI)
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients 12 years of age or older
Initial presentation of acute GVHD after allogeneic hematopoietic cell transplantation for any indication
Any graft or donor source or conditioning intensity
Clinical diagnosis of acute GVHD requiring systemic therapy with corticosteroids
You may not be if
Prior exogenous AAT exposure for GVHD prophylaxis
Relapsed, progressing, or persistent malignancy
de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment
Receiving other drugs for the treatment of GVHD
Receiving systemic CS for any indication within 7 days before the onset of acute GVHD
Clareo Health | Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone
